(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 March 2022 (03.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/046650 A1

(51) International Patent Classification:
A61K 31/505 (2006.01) *A61P 35/00* (2006.01)
A61K 45/06 (2006.01) *A61P 43/00* (2006.01)

(21) International Application Number:
PCT/US2021/047178

(22) International Filing Date:
23 August 2021 (23.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/069,472 24 August 2020 (24.08.2020) US

(71) Applicant: **CURTANA PHARMACEUTICALS, INC.** [US/US]; 4200 Marathon Blvd., Suite 200, Austin, Texas 78756 (US).

(72) Inventors: **BEATON, Graham**; 4200 Marathon Blvd., Suite 200, Austin, Texas 78756 (US). **STEIN, Gregory Douglas**; 4200 Marathon Blvd., Suite 200, Austin, Texas 78756 (US). **ALTON, Gordon Robert**; 4200 Marathon Blvd., Suite 200, Austin, Texas 78756 (US).

(74) Agent: **ADRIANOWYCZ, Matthew A.**; Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/046650 A1

(54) Title: COMBINATION THERAPIES WITH OLIG2 INHIBITORS

(57) Abstract: Described herein are pharmaceutical compositions containing compounds which inhibit the activity of Olig2 in combination with a second therapeutic agent. Also described herein are methods of using such pharmaceutical compositions for treating cancer and other diseases.